Inserm presentation
Contents

• Address major biomedical research challenges
• Take action to improve the health of all
• Disseminate knowledge for the benefit of all

2021 figures, unless otherwise stated
Address major biomedical research challenges
Be a reference in biomedical research

<table>
<thead>
<tr>
<th>In Europe and worldwide</th>
<th>In France</th>
<th>Patents and licenses</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 6,750 international cooperation agreements with more than 100 countries <em>(in 2020)</em></td>
<td>• 256 research units</td>
<td>• A portfolio of 2,153 patent families</td>
</tr>
<tr>
<td>• 1 thematic coordination program, 12 new first-step projects and 12 new European and international research projects or networks <em>(in 2022)</em></td>
<td>• 35 clinical investigation centers</td>
<td>• 62 new license agreements signed</td>
</tr>
<tr>
<td>• 2 joint research units abroad</td>
<td>• 45 service units</td>
<td>• 360 R&amp;D partnerships</td>
</tr>
</tbody>
</table>

**14,292 staff**

- 5,077 civil servants (2,174 researchers, ATIP-Avenir contracts included)
- 3,325 contract staff and temporary workers (incl. ATIP-Avenir contracts)
  > 50 ATIP-Avenir contracts
- 5,890* teacher-researchers and hospital teachers

**A budget of €1,161 million**

- €701 million from government subsidies
- €460 million from internal resources

**In France**

- 256 research units
- 35 clinical investigation centers
- 45 service units

**Patents and licenses**

- A portfolio of 2,153 patent families
- 62 new license agreements signed
- 360 R&D partnerships

* Temporary 2022 figure
Address major biomedical research challenges

Be a reference in biomedical research (2)

In Europe
- No. 1 academic applicant in the biomedical sector in Europe
- No. 2 European applicant in the biotechnology sector
- No. 3 European applicant in the pharmaceutical sector
- 396 H2020 contracts, 149 within the Health social challenge, and 34 coordinated by Inserm (No. 1 in Europe)
- 97 ERC grant recipients managed by Inserm
- 53 Marie Skłodowska-Curie individual grants
- participation in 44 innovative training networks (ITN)

Close dialogue
with over 500 patient organizations for
- participatory research
- meetings and debates between patients and researchers

13,976 original articles
Address major biomedical research challenges

Make changes to adapt

- 1964: Inserm is created
- 1983: Public scientific and technological institute, entirely dedicated to human health and biomedical research
- 2009: Inserm, following reform, ensures the strategic, scientific and operational coordination of biomedical research
- 2014: Inserm celebrates its 50th anniversary
- 2019: Inserm establishes its 2025 Strategic plan with the French State
- 2022: Inserm establishes its 2021-2025 Objectives, resources and performance contract
Address major biomedical research challenges

Our organization

Thematic Institutes
- Neurosciences, Cognitive Sciences, Neurology, Psychiatry
- Cancer
- Immunology, Inflammation, Infectious Diseases and Microbiology
- Pathophysiology, Metabolism, Nutrition
- Public Health
- Health Technologies
- Molecular and Structural Basis of Living Organisms
- Cell Biology, Development and Evolution
- Genetics, Genomics and Bioinformatics

Divisions
- Financial Affairs
- Legal Affairs
- Program Assessment and Follow-Up
- Scientific Information and Communication
- Partnership and External Relations
- Human Resources
- Information Systems
- Chief Accounting Department

Regional Offices
- Île-de-France (4)
- Auvergne-Rhône-Alpes
- Est
- Grand Ouest
- Occitanie Méditerranée
- Occitanie Pyrénées
- Nord-Ouest
- Nouvelle-Aquitaine
- Provence, Alpes, Côte d’Azur and Corsica
Address major biomedical research challenges

Our presence in France

256 research units
45 service units
35 clinical investigation centers

Inserm
Address major biomedical research challenges

Our presence in France (2)

83% of Inserm strengths

13 research universities in which Inserm invests more than €10M each year
Our main partners

- **34** universities

- A key partner of **13** research universities in which Inserm invests more than €10M each year

- On **14** Idex and I-sites, Inserm invests **78%** of its resources

- Research units in **30** teaching hospitals

- Founding members of Aviesan alongside Inserm: CEA / CNRS / INRAE / INRIA / Institut Pasteur / IRD / CPU / CHRU and the associate members

- Other alliances: AllEnvi, Allistène, Athéna

- Industry: Astra Zeneca/MedImmune, Dassault System 3DS, MSD Avenir, Sanofi...

- Foundations and associations: Fondation Bettencourt Schueller, FRM...

- European and international academic institutions: Helmholtz…
Address major biomedical research challenges

Our presence in Europe

- Research teams: informal **scientific cooperation** with their partners
- Institutional **partnership agreements** and **specific collaborative networks** in Europe: 2 European laboratories within a single thematic coordination program, 13 leading international research projects (IRP) and 2 within a single international research network (IRN)
Our presence in the world

- Research teams: informal **scientific cooperation** with their partners
- Institutional **partnership agreements** and **specific collaborative networks** outside Europe: 2 non-European laboratories within a single thematic coordination program, 18 leading international research projects (IRP) et 1 within an international research network (IRN)
Take action to improve the health of all
Our missions for health

- Take action to improve the health of all

**INITIATE, DEVELOP AND COORDINATE BIOMEDICAL RESEARCH OF EXCELLENCE**

- Produce and disseminate knowledge nationally and internationally
- Play a major role in the national coordination of health research
- Support higher education and research training
- Provide scientific expertise and support for science based policy in health
- Create value from discoveries and their applications
Take action to improve the health of all

Our fields of activity and expertise

- Fundamental research
- Clinical and preclinical trials
- Cohorts and epidemiological studies
- Provision of expertise and contribution to public health and research policy
- Biomedical research infrastructure
- Technology transfer
Cohorts and epidemiological studies

- **EpiCOV**: Over 130,000 volunteers for research on SARS-CoV-2
- **ELFE**: 20,000 children born in 2011, longitudinal study from birth to adult age
- **Constances**: 200,000 subjects representative of the French population, aged 18 to 69 years + a biobank of 100,000 subjects
- **RaDiCo**: Over 5,000 people with rare diseases in 12 cohorts
- **Databases, accessible online**
  - **Epidemiologie-France portal**: French health database catalogue > epidemiologie-france.aviesan.fr
  - **CépiDc**: Epidemiology center on the medical causes of death > cepidc.inserm.fr
  - **Orphanet**: Portal for rare diseases and orphan drugs > orpha.net

Over 1.6 million people (2% of the French population) participating in Inserm cohorts

- Take action to improve the health of all
Take action to improve the health of all

A continuum from basic to clinical, therapeutic, and public health research

- Basic research
- Preclinical Studies Proof of concept
- Phases I, IIa, IIb, III
- Phase IV

- 256 research units
- National research infrastructures
- 35 clinical research centers
- About 90 cohorts & large scale studies
- Take action to improve the health of all

**Value creation activities which are bearing fruit**

- **2,153** patent families portfolio
- **130** new patent families in 2021
  - An annual budget of **€1.6 M** to fund project maturation or proof of concept
  - A maturation budget reaching **€21.7 M** invested in 336 projects since 2009
- **€445 M** industrial partnerships since 2010 (patents, research contracts)
- **€6-12 M** per year from licensing agreements
- **Over 400** technologies and research tools available for licensing
  - Strategic alliances with, for example: Astra Zeneca/MedImmune, Dassault System 3DS, MSD Avenir, Sanofi
- 10 start-up created each year via Inserm Transfert (Inserm’s subsidiary)
- Partnerships with SATTs
Take action to improve the health of all

Inserm & Inserm Transfert in EPO rankings

- No. 3 European applicant in the pharmaceutical sector (in the Top 3 since 2015)*
- No. 2 European applicant in the biotechnology sector (3rd year)*
- No. 1 European research academic institution in the biomedical sector*
- 2,153 patent families as of 31/12/2021

* European Patent Office (EPO) 2021 rankings

8th in France all sectors represented
Inserm Transfert: partnering with industries

Some of our industrial partners: Privileged partner of major industrials, mid-size, SME, involved in human health, at the international level

- Roche
- MedImmune
- Baxter
- Fresenius
- Janssen
- ultragenyx
- Tri
daB
- AstraZeneca
- Johnson & Johnson Innovation
- Lilly
- sanofi
- Quest Diagnostics
- ILiAD
- Boehringer Ingelheim
- gsk
- GlaxoSmithKline
- GILEAD
- Qiagen
- Bristol Myers Squibb
- MSD
- abbvie
- Otsuka
- Vivre mieux
- Lundbeck
- Shire
- AMGEN
Take action to improve the health of all

Inserm spin-offs based on inventors as drivers
Major discoveries

Since its foundation in 1964, Inserm has played a part in many key, historic medical advances, such as:

- the first prenatal diagnostic tests;
- understanding the HLA system and the ensuing immune reactions;
- the first in vitro fertilization;
- identification of HIV;
- radiotherapy for cancer;
- the first skin graft;
- deep brain stimulation in the treatment of Parkinson’s disease;
- gene therapy…
Disseminate knowledge for the benefit of all
Inserm fulfils its mission of expertise provision and knowledge transfer to decision-makers in the field of public health by providing the scientific insight required to take decisions on public health policy issues.
Our work with patient organizations

Towards research in partnership with patient organizations and civil society collectives

• Promote meetings and direct dialogue between researchers and collectives
• Act for the structuring, coordination and animation of participatory research projects
• Help to better take into account these projects in the assessment of researchers and structures
• Facilitate access to scientific information for society
Our presence in the service of public information

- disseminate knowledge for the benefit of all

**Inserm.fr**
- **13,204,000** sessions
- **110,000** followers

**LinkedIn**
- **110,000** followers

**Twitter**
- **155,000** followers

**Facebook**
- **49,000** followers

**Instagram**
- **11,000** followers

**YouTube**
- **270,000** followers

- Live lectures and 30' Santé broadcast
  - **18,000** views

- Public events
  - + than **2 millions** participants and views

- Patient organization training seminars
  - **1,100** participants *

- Canal Détox information videos and articles
  - + than **1.2 million** views

* 2020 figures